Intensive insulin rx lowers glycemic variability in early DM

April 15, 2014
Intensive insulin rx lowers glycemic variability in early DM

(HealthDay)—Short-term intensive insulin therapy (IIT) can improve β-cell function in type 2 diabetes mellitus (T2DM) in association with decreased glycemic variability, according to a study published in the April issue of Diabetes Care.

Caroline K. Kramer, M.D., Ph.D., from Mount Sinai Hospital in Toronto, and colleagues examined whether β-cell functional recovery induced by short-term IIT correlated with glycemic variability. Sixty-one patients with T2DM (mean duration, three years) underwent four weeks of IIT. β- was assessed with the Insulin Secretion-Sensitivity Index-2 (ISSI-2) before and after IIT. Glucose variability was measured in the first and last week by the coefficient of variation of capillary glucose.

The researchers found that 55.7 percent of had a reduction in their glucose variability between the first and last week on IIT. There was a negative correlation between change in glucose variability and the change in β-cell function (P = 0.008). The only factor independently associated with the change in glucose variability was percentage change in ISSI-2 (P = 0.03). Patients with a 25 percent or higher increase in ISSI-2 had a reduction in glucose variability, compared with their peers who had virtually no change (−0.041 versus −0.0002; P = 0.006).

"It thus emerges that early in the course of T2DM, glucose variability is a modifiable parameter for which intervention may mitigate future risk of adverse outcomes," the authors write.

Two authors disclosed financial ties to Novo Nordisk, which funded the study.

Explore further: Glycemic variability affects mood and quality of life

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Glycemic variability affects mood and quality of life

May 10, 2012
(HealthDay) -- Glycemic variability appears to be associated with lower quality of life and negative moods in women with type 2 diabetes, according to a study published in the March 30 issue of Diabetes Technology & Therapeutics.

Insulin LY2605541 tops glargine for glycemic control in T1DM

January 13, 2013
(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 ...

Fat, protein impact postprandial glucose excursion in T1DM

December 19, 2013
(HealthDay)—For children with type 1 diabetes using intensive insulin therapy (IIT), high-fat (HF) and high-protein (HP) meals increase glucose excursions, with an additive effect observed, according to a study published ...

Measures of glucose and its variability are inter-related

September 11, 2013
(HealthDay)—Hemoglobin A1c (HbA1c) and glycated albumin (GA) are inter-related and correlate with retinopathy and nephropathy, while only HbA1c correlates with cardiovascular disease, according to a study published online ...

Exercise-induced improvements in glycemic control and type 2 diabetes

July 1, 2013
Exercise-induced improvements in glycemic control are dependent on the pre-training glycemic level, and although moderate-intensity aerobic exercise can improve glycemic control, individuals with ambient hyperglycemia (high ...

Absolute incretin effect reduced in type 2 diabetes

June 25, 2012
(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) the absolute incretin effect is reduced compared with healthy individuals, but its relative importance is increased, particularly in first-phase insulin secretion, ...

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.